PureTech Health PLC PureTech to Present at Cowen & Co. Conference

TIDMPRTC

PureTech Health PLC

24 February 2017

PureTech Health plc

PureTech Health to Present at the Cowen and Company 37th Annual Health Care Conference

PureTech Health plc (LSE: PRTC), a cross-disciplinary biopharmaceutical company, today announced that Daphne Zohar, PureTech Health's Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Monday, 6 March, at 3:20pm EST.

A webcast of the presentation will be available at http://puretechhealth.com/investors.php under the Reports and Presentations tab.

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary biopharmaceutical company creating 21(st) century medicines that modulate the adaptive human systems. Our therapies target the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. We have multiple human proof-of-concept studies and pivotal or registration studies expected to read out in the next two years. PureTech Health's rich and growing research and development pipeline has been developed in collaboration with some of the world's leading scientific experts who, along with PureTech's experienced team and board, analyse more than 650 scientific discoveries per year to identify and advance only the opportunities we believe hold the most promise for patients. This team and process place PureTech Health on the cutting edge of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter.

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:

 
              PureTech Health             FTI Consulting 
     Media:   Allison Mead                Ben Atwell 
               +1 617 651 3156             +44 (0) 20 3727 
               amead@puretechhealth.com    1000 
 Investors:   Graham Morrell 
               +1 617 986 1659 
               gm@puretechhealth.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRALFFVIFSIVFID

(END) Dow Jones Newswires

February 24, 2017 02:01 ET (07:01 GMT)

Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024